Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Casirivimab/imdevimab for COVID-19: real-time meta analysis of 26 studies
Covid Analysis (Preprint) (meta analysis)
Covid Analysis, Casirivimab/imdevimab for COVID-19: real-time meta analysis of 26 studies, (Preprint) (meta analysis)
Mar 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
• Statistically significant improvements are seen for mortality, hospitalization, progression, recovery, cases, and viral clearance. 19 studies from 13 independent teams in 4 different countries show statistically significant improvements in isolation (11 for the most serious outcome).
• Meta analysis using the most serious outcome reported shows 53% [33‑66%] improvement. Results are similar for Randomized Controlled Trials, similar after exclusions, and similar for peer-reviewed studies.
• Results are robust — in exclusion sensitivity analysis 12 of 26 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
• Efficacy is variant dependent. In Vitro studies suggest a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan]. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape [Choudhary]. ADE shown In Vitro [Shimizu].
• No treatment, vaccine, or intervention is 100% effective and available. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. Only 27% of casirivimab/imdevimab studies show zero events with treatment.
• All data to reproduce this paper and sources are in the appendix.
Percentage improvement with casirivimab/imdevimab (more)
All studiesEarly treatmentProphylaxisStudies Patients Authors
All studies53% [33‑66%]****47% [25‑62%]***93% [79‑97%]**** 2654,453 386
Randomized Controlled TrialsRCTs61% [32‑78%]***63% [42‑76%]****93% [79‑97%]**** 921,306 178
Mortality40% [1‑64%]*65% [-6‑88%]- 832,929 216
HospitalizationHosp.42% [17‑59%]**39% [9‑59%]*92% [-36‑100%] 1246,106 133
Cases80% [39‑93%]**33% [2‑57%]85% [74‑91%]**** 43,265 71
Covid Analysis et al., Mar 2023, preprint, 1 author.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit